Literature DB >> 10064148

Dynorphin A increases substance P release from trigeminal primary afferent C-fibers.

J L Arcaya1, G Cano, G Gómez, W Maixner, H Suárez-Roca.   

Abstract

Dynorphin A-(1-17) has been found to produce spinal antianalgesia and allodynia. Thus, we studied whether dynorphin A-(1-17) modulates substance P release evoked by the C-fiber-selective stimulant capsaicin (1 microM) from trigeminal nucleus caudalis slices. Very low concentrations of dynorphin A-(1-17) (0.01-0.1 nM) strongly facilitated capsaicin-evoked substance P release. This dynorphin A-(1-17) effect was not blocked by the opioid receptor antagonists naloxone (100 nM), beta-funaltrexamine (20 nM), naloxonazine (1 nM), nor-binaltorphimine (3 nM) and ICI 174,864 (N,N-dialyl-Tyr-Aib-Phe-Leu; 0.3 microM). Yet, the effect of dynorphin A-(1-17) was blocked by the NMDA receptor antagonist MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5-10-imine maleate; 0.3 microM). Neonatal treatment with capsaicin (50 mg/kg s.c.), which destroys substance P-containing primary afferents, abolished the excitatory effect of dynorphin A-(1-17) on K+-evoked substance P release. In conclusion, dynorphin A-(1-17) increases substance P release from C-fibers by the activation of NMDA receptors which supports the involvement of presynaptic mechanisms in dynorphin-induced antianalgesia and allodynia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064148     DOI: 10.1016/s0014-2999(98)00897-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Authors:  T W Vanderah; L R Gardell; S E Burgess; M Ibrahim; A Dogrul; C M Zhong; E T Zhang; T P Malan; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

2.  Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation.

Authors:  L R Gardell; T W Vanderah; S E Gardell; R Wang; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

3.  Bi-phasic intensity-dependent opioid-mediated neural amplitude changes in the chinchilla cochlea: partial blockade by an N-Methyl-D-Aspartate (NMDA)-receptor antagonist.

Authors:  Tony L Sahley; David J Anderson; Cheryl L Chernicky
Journal:  Eur J Pharmacol       Date:  2007-10-25       Impact factor: 4.432

Review 4.  Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia.

Authors:  D Eric Brush
Journal:  J Med Toxicol       Date:  2012-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.